Sravan Emany - Beam Therapeutics Chief Officer
| BEAM Stock | USD 27.28 1.37 5.29% |
Executive
Sravan Emany is Chief Officer of Beam Therapeutics
| Age | 47 |
| Phone | 857 327 8775 |
| Web | https://beamtx.com |
Sravan Emany Latest Insider Activity
Tracking and analyzing the buying and selling activities of Sravan Emany against Beam Therapeutics stock is an integral part of due diligence when investing in Beam Therapeutics. Sravan Emany insider activity provides valuable insight into whether Beam Therapeutics is net buyers or sellers over its current business cycle. Note, Beam Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Beam Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Sravan Emany over three weeks ago Acquisition by Sravan Emany of 80000 shares of Beam Therapeutics subject to Rule 16b-3 | ||
Sravan Emany over a month ago Insider Trading | ||
Sravan Emany over two months ago Disposition of 11001 shares by Sravan Emany of Ironwood Pharmaceuticals at 4.08 subject to Rule 16b-3 | ||
Sravan Emany over six months ago Disposition of 18280 shares by Sravan Emany of Ironwood Pharmaceuticals at 6.64 subject to Rule 16b-3 |
Beam Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0928) % which means that it has lost $0.0928 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1829) %, meaning that it created substantial loss on money invested by shareholders. Beam Therapeutics' management efficiency ratios could be used to measure how well Beam Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Barbara Hickingbottom | Fate Therapeutics | N/A | |
| Christian MBA | Sana Biotechnology | 41 | |
| Sonja MD | Sana Biotechnology | 50 | |
| Linea Aspesi | Editas Medicine | 55 | |
| Susie CFA | Vertex Pharmaceuticals | N/A | |
| Stephen Kennedy | Crispr Therapeutics AG | N/A | |
| Stephanie Franklin | Vertex Pharmaceuticals | N/A | |
| Anna Wagner | Ginkgo Bioworks Holdings | N/A | |
| Julianne MBA | Crispr Therapeutics AG | N/A | |
| Timothy MBA | Caribou Biosciences | 56 | |
| Meredith Goldwasser | Prime Medicine, Common | 54 | |
| Joaquim Marques | Ginkgo Bioworks Holdings | N/A | |
| Cristi Barnett | Editas Medicine | N/A | |
| Daniel Poon | Caribou Biosciences | N/A | |
| James JD | Crispr Therapeutics AG | 53 | |
| MD FACP | Crispr Therapeutics AG | 50 | |
| JD Esq | Caribou Biosciences | 70 | |
| Karen JD | Prime Medicine, Common | N/A | |
| Richard Mulligan | Sana Biotechnology | 69 | |
| Jonathan JD | Vertex Pharmaceuticals | 61 | |
| Samarth Kulkarni | Crispr Therapeutics AG | 47 | |
Management Performance
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0928 |
Beam Therapeutics Leadership Team
Elected by the shareholders, the Beam Therapeutics' board of directors comprises two types of representatives: Beam Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Beam. The board's role is to monitor Beam Therapeutics' management team and ensure that shareholders' interests are well served. Beam Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Beam Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Manmohan Singh, Chief Officer | ||
| Nicole Gaudelli, CoFounder | ||
| Brian Riley, VP Operations | ||
| Susan OConnor, Chief Officer | ||
| Alexis Komor, CoFounder | ||
| Amy MD, Chief Officer | ||
| Suzanne Fleming, Chief Officer | ||
| Sravan Emany, Chief Officer | ||
| TerryAnn MBA, CFO Treasurer | ||
| Giuseppe Ciaramella, Pres Officer | ||
| David Liu, CoFounder | ||
| Feng Zhang, CoFounder | ||
| John MBA, CEO Director | ||
| Bethany Cavanagh, Senior Treasurer | ||
| Gopi Shanker, Chief Officer | ||
| Dr JD, Chief VP |
Beam Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Beam Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0928 | ||||
| Profit Margin | (0.41) % | ||||
| Operating Margin | (7.46) % | ||||
| Current Valuation | 1.38 B | ||||
| Shares Outstanding | 82.81 M | ||||
| Shares Owned By Insiders | 1.40 % | ||||
| Shares Owned By Institutions | 93.71 % | ||||
| Number Of Shares Shorted | 10.79 M | ||||
| Price To Earning | 37.48 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.